PCN95 Effect of Earlier Use of Ibrutinib on Healthcare Resource Utilization (HRU) and Costs Among Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in the United States
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.187
https://www.valueinhealthjournal.com/article/S1098-3015(21)00404-6/fulltext
Title :
PCN95 Effect of Earlier Use of Ibrutinib on Healthcare Resource Utilization (HRU) and Costs Among Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00404-6&doi=10.1016/j.jval.2021.04.187
First page :
Section Title :
Open access? :
No
Section Order :
10763